PRTA

Prothena Corporation plc

21.62 USD
-1.01 (-4.46%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Prothena Corporation plc stock is up 1.55% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 58.33% of the previous 11 May’s closed higher than April. In the last 8 Unusual Options Trades, there were 2 CALLs, 6 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
28 Mar 18:01 17 Jan, 2025 40.00 CALL 102 9
28 Mar 18:01 17 Jan, 2025 40.00 CALL 95 9
10 Apr 14:04 16 Jan, 2026 35.00 PUT 70 0
16 Apr 13:59 16 Jan, 2026 30.00 PUT 25 150
16 Apr 14:04 16 Jan, 2026 35.00 PUT 80 110
16 Apr 14:04 16 Jan, 2026 35.00 PUT 30 110
07 May 19:55 20 Sep, 2024 35.00 PUT 30 0
20 May 14:13 20 Dec, 2024 35.00 PUT 24 4

About Prothena Corporation plc

Prothena Corporation plc focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, is in clinical trials for Parkinson's disease; PRX004, which completed Phase I clinical trial.

  • JP Morgan
    Thu May 9, 14:39
    buy
    confirm
  • HC Wainwright & Co.
    Thu May 9, 13:55
    buy
    confirm